{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:02:29Z","timestamp":1789729349658,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"City of Hope"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Oral cavity squamous cell carcinoma (OCSCC) is a common epithelial malignancy for which site-specific biomarkers with proven prognostic utility remain limited. In this study, we present one of the largest single-center, site-specific molecular analyses of OCSCC to date. Using two separate versions of multigene next-generation sequencing (NGS), we sought to identify a focused set of clinically actionable and widely accessible biomarkers that could support diagnosis, prognostication, and therapeutic decision-making. Our findings highlight the potential of a limited molecular panel to capture key prognostic information, supporting a more accessible and scalable approach to precision oncology in OCSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Seventy-three adult patients (ages 19\u201385 years) with site-specific OCSCC treated at City of Hope between 2019 and 2023 were included. Tissue specimens were collected at initial diagnosis or recurrence and analyzed using NGS panels for both DNA and RNA. Sequencing identified single nucleotide variants, copy number alterations, and gene fusions. Associations between genomic alterations and overall survival (OS) were assessed using Kaplan\u2013Meier curves and log-rank tests with significance set at\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>TP53<\/jats:italic>\n                      and\n                      <jats:italic>TERT<\/jats:italic>\n                      -promoter oncogenic variants were the most frequent alterations, co-occurring in 64.4% of cases regardless of disease stage (primary vs. recurrence). Pathogenic variants in\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      ,\n                      <jats:italic>HRAS<\/jats:italic>\n                      ,\n                      <jats:italic>PIK3CA<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA1<\/jats:italic>\n                      , and\n                      <jats:italic>CASP8<\/jats:italic>\n                      were enriched among patients who developed recurrence. In this group, copy number amplification of\n                      <jats:italic>CCND1<\/jats:italic>\n                      ,\n                      <jats:italic>FGF3<\/jats:italic>\n                      ,\n                      <jats:italic>FGF4<\/jats:italic>\n                      ,\n                      <jats:italic>FGF19<\/jats:italic>\n                      ,\n                      <jats:italic>RPS6KA4<\/jats:italic>\n                      ,\n                      <jats:italic>RPS6KB2<\/jats:italic>\n                      , and\n                      <jats:italic>MYC<\/jats:italic>\n                      , along with copy number loss of\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      and\n                      <jats:italic>CDKN2B<\/jats:italic>\n                      , were observed. Lower PD-L1 expression, absence of\n                      <jats:italic>TERT<\/jats:italic>\n                      -promoter mutations (PMs), and focal amplification of 11q13 were associated with poor overall survival in univariate analysis (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Multigene NGS profiling revealed recurrent genomic alterations and prognostic biomarkers in OCSCC. Based on these findings, we propose an initial biomarker panel comprising TP53 and PD-L1 (22C3 clone) immunostains, along with TP53 and TERT PM analysis. Collectively, these assays capture key prognostic biomarkers associated with adverse outcomes, including low PD-L1 expression (CPS\u2009&lt;\u200920) and the absence of TERT PMs in relation to overall survival. In addition, copy-number assessment of 11q13, MYC (8q), and CDKN2A (9p) may warrant further investigation for future clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12105-026-01968-2","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:06:18Z","timestamp":1789725978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Accessible Approach to Molecular and Biomarker Testing for Risk Stratification in Oral Cavity Squamous Cell Carcinoma"],"prefix":"10.1007","volume":"20","author":[{"given":"Michelle","family":"Afkhami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Telatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Arias-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mehrazma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Massarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tizro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. M.","family":"Villaflor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"1968_CR1","unstructured":"SEER Cancer Stat Facts: Oral Cavity and Pharynx Cancer [September 4 2023]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/oralcav.html"},{"issue":"1","key":"1968_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.canlet.2016.09.014","volume":"383","author":"TF Hayes","year":"2016","unstructured":"Hayes TF, Benaich N, Goldie SJ, Sipil\u00e4 K, Ames-Draycott A, Cai W et al (2016) Integrative genomic and functional analysis of human oral squamous cell carcinoma cell lines reveals synergistic effects of FAT1 and CASP8 inactivation. Cancer Lett 383(1):106\u2013114","journal-title":"Cancer Lett"},{"key":"1968_CR3","doi-asserted-by":"publisher","first-page":"603160","DOI":"10.3389\/froh.2020.603160","volume":"1","author":"S Usman","year":"2020","unstructured":"Usman S, Jamal A, Teh MT, Waseem A (2020) Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance. Front Oral Health 1:603160","journal-title":"Front Oral Health"},{"key":"1968_CR4","doi-asserted-by":"publisher","first-page":"153474","DOI":"10.1016\/j.prp.2021.153474","volume":"223","author":"YH Wu-Chou","year":"2021","unstructured":"Wu-Chou YH, Hsieh CH, Liao CT, Lin YT, Fan WL, Yang CH (2021) NOTCH1 mutations as prognostic marker in oral squamous cell carcinoma. Pathol Res Pract 223:153474","journal-title":"Pathol Res Pract"},{"issue":"5","key":"1968_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.oraloncology.2014.02.005","volume":"50","author":"I Salahshourifar","year":"2014","unstructured":"Salahshourifar I, Vincent-Chong VK, Kallarakkal TG, Zain RB (2014) Genomic DNA copy number alterations from precursor oral lesions to oral squamous cell carcinoma. Oral Oncol 50(5):404\u2013412","journal-title":"Oral Oncol"},{"issue":"7","key":"1968_CR6","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-17-0721","volume":"24","author":"VC Sandulache","year":"2018","unstructured":"Sandulache VC, Michikawa C, Kataria P, Gleber-Netto FO, Bell D, Trivedi S et al (2018) High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. Clin Cancer Res 24(7):1727\u20131733","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1968_CR7","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin 67(2):93\u201399","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"1968_CR8","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/ijms20215452","volume":"20","author":"F Pagni","year":"2019","unstructured":"Pagni F, Guerini-Rocco E, Schultheis AM, Grazia G, Rijavec E, Ghidini M et al (2019) Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. Int J Mol Sci 20(21):5452","journal-title":"Int J Mol Sci"},{"key":"1968_CR9","doi-asserted-by":"publisher","first-page":"viii729","DOI":"10.1093\/annonc\/mdy424.045","volume":"29","author":"B Burtness","year":"2018","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, De Castro G Jr. et al (2018) KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC). Ann Oncol 29:viii729","journal-title":"Ann Oncol"},{"issue":"4","key":"1968_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/cas.12369","volume":"105","author":"H Maruyama","year":"2014","unstructured":"Maruyama H, Yasui T, Ishikawa-Fujiwara T, Morii E, Yamamoto Y, Yoshii T et al (2014) Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci 105(4):409\u2013417","journal-title":"Cancer Sci"},{"key":"1968_CR11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1200\/PO.20.00515","volume":"5","author":"Y Yu","year":"2021","unstructured":"Yu Y, Fan D, Song X, Zakeri K, Chen L, Kang J et al (2021) TERT promoter mutations are enriched in oral cavity cancers and associated with locoregional recurrence. JCO Precis Oncol 5:1259\u20131269","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"1968_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jaad.2018.08.032","volume":"80","author":"MA Campos","year":"2019","unstructured":"Campos MA, Macedo S, Fernandes M, Pestana A, Pardal J, Batista R et al (2019) TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma. J Am Acad Dermatol 80(3):660\u2013669","journal-title":"J Am Acad Dermatol"},{"key":"1968_CR13","doi-asserted-by":"publisher","first-page":"e07918","DOI":"10.7554\/eLife.07918","volume":"4","author":"K Chiba","year":"2015","unstructured":"Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D (2015) Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife 4:e07918","journal-title":"Elife"},{"issue":"2 Pt 1","key":"1968_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/0092-8674(85)90170-9","volume":"43","author":"CW Greider","year":"1985","unstructured":"Greider CW, Blackburn EH (1985) Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43(2 Pt 1):405\u2013413","journal-title":"Cell"},{"issue":"6122","key":"1968_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957\u2013959","journal-title":"Science"},{"issue":"10","key":"1968_CR16","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/bjc.2014.538","volume":"111","author":"M Labussi\u00e8re","year":"2014","unstructured":"Labussi\u00e8re M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S et al (2014) TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 111(10):2024\u20132032","journal-title":"Br J Cancer"},{"issue":"6","key":"1968_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00401-017-1690-1","volume":"133","author":"M Pekmezci","year":"2017","unstructured":"Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H et al (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133(6):1001\u20131016","journal-title":"Acta Neuropathol"},{"key":"1968_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3389\/fonc.2020.01275","volume":"10","author":"L Arantes","year":"2020","unstructured":"Arantes L, Cruvinel-Carloni A, de Carvalho AC, Sorroche BP, Carvalho AL, Scapulatempo-Neto C et al (2020) TERT Promoter Mutation C228T Increases Risk for Tumor Recurrence and Death in Head and Neck Cancer Patients. Front Oncol 10:1275","journal-title":"Front Oncol"},{"issue":"2","key":"1968_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00432-020-03130-z","volume":"146","author":"P Boscolo-Rizzo","year":"2020","unstructured":"Boscolo-Rizzo P, Giunco S, Rampazzo E, Brutti M, Spinato G, Menegaldo A et al (2020) TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 146(2):381\u2013389","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"1968_CR20","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/hed.24728","volume":"39","author":"KP Chang","year":"2017","unstructured":"Chang KP, Wang CI, Pickering CR, Huang Y, Tsai CN, Tsang NM et al (2017) Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. Head Neck 39(6):1131\u20131137","journal-title":"Head Neck"},{"key":"1968_CR21","doi-asserted-by":"publisher","first-page":"152104","DOI":"10.1016\/j.anndiagpath.2023.152104","volume":"63","author":"M Afkhami","year":"2023","unstructured":"Afkhami M, Maghami E, Gernon TJ, Villaflor V, Bell D (2023) Wolf in sheep\u2019s clothing - Oral proliferative verrucous leukoplakia: Progression with longitudinal molecular insights. Ann Diagn Pathol 63:152104","journal-title":"Ann Diagn Pathol"},{"issue":"3","key":"1968_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/odi.15124","volume":"31","author":"HJ Lu","year":"2025","unstructured":"Lu HJ, Su CW, Su SC, Chang LC, Wu MF, Lin CW et al (2025) Prognostic impact of caspase-8 mutation in oral cavity squamous cell carcinoma. Oral Dis 31(3):769\u2013781","journal-title":"Oral Dis"},{"issue":"1","key":"1968_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s44197-021-00016-2","volume":"12","author":"C Irawan","year":"2022","unstructured":"Irawan C, Benbella LG, Rachman A, Mansjoer A (2022) Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients. J Epidemiol Glob Health 12(1):16\u201324","journal-title":"J Epidemiol Glob Health"},{"issue":"21","key":"1968_CR24","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1200\/JCO.21.02198","volume":"40","author":"B Burtness","year":"2022","unstructured":"Burtness B, Rischin D, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr. et al (2022) Pembrolizumab Alone or With Chemotherapy for Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol 40(21):2321\u20132332","journal-title":"J Clin Oncol"},{"issue":"1","key":"1968_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41467-024-55316-5","volume":"16","author":"M Gounder","year":"2025","unstructured":"Gounder M, Johnson M, Heist RS, Shapiro GI, Postel-Vinay S, Wilson FH et al (2025) MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial. Nat Commun 16(1):423","journal-title":"Nat Commun"},{"issue":"1","key":"1968_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41467-022-29397-z","volume":"13","author":"O Alhalabi","year":"2022","unstructured":"Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S et al (2022) MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797","journal-title":"Nat Commun"},{"issue":"3","key":"1968_CR27","doi-asserted-by":"publisher","first-page":"e517160","DOI":"10.1200\/EDBK-26-517160","volume":"46","author":"TA Yap","year":"2026","unstructured":"Yap TA, Simpkins F, Porte M, Postel-Vinay S (2026) Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology. Am Soc Clin Oncol Educ Book 46(3):e517160","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"1968_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00428-015-1719-6","volume":"466","author":"R Noorlag","year":"2015","unstructured":"Noorlag R, van Kempen PM, Stegeman I, Koole R, van Es RJ, Willems SM (2015) The diagnostic value of 11q13 amplification and protein expression in the detection of nodal metastasis from oral squamous cell carcinoma: a systematic review and meta-analysis. Virchows Arch 466(4):363\u2013373","journal-title":"Virchows Arch"},{"issue":"6","key":"1968_CR29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/cancers11060760","volume":"11","author":"HT Chien","year":"2019","unstructured":"Chien HT, Cheng SD, Liao CT, Wang HM, Huang SF (2019) Amplification of the EGFR and CCND1 are coordinated and play important roles in the progression of oral squamous cell carcinomas. Cancers (Basel) 11(6):760","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1968_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/jcm7120501","volume":"7","author":"F Hermida-Prado","year":"2018","unstructured":"Hermida-Prado F, Men\u00e9ndez ST, Albornoz-Afanasiev P, Granda-Diaz R, \u00c1lvarez-Teijeiro S, Villaronga M et al (2018) Distinctive expression and amplification of genes at 11q13 in relation to HPV status with impact on survival in head and neck cancer patients. J Clin Med 7(12):501","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"1968_CR31","first-page":"E1192","volume":"38","author":"VB Wreesmann","year":"2016","unstructured":"Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, G\u00f6nen M et al (2016) Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. Head Neck 38(Suppl 1):E1192\u2013E1199","journal-title":"Head Neck"},{"issue":"7","key":"1968_CR32","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/S1470-2045(24)00066-4","volume":"25","author":"C Henson","year":"2024","unstructured":"Henson C, Abou-Foul AK, Yu E, Glastonbury C, Huang SH, King AD et al (2024) Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol 25(7):e297\u2013e307","journal-title":"Lancet Oncol"},{"key":"1968_CR33","doi-asserted-by":"publisher","first-page":"153934","DOI":"10.1016\/j.prp.2022.153934","volume":"236","author":"D Wusiman","year":"2022","unstructured":"Wusiman D, Guo L, Huang Z, Li Z, Liu S, Ying J et al (2022) The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma. Pathol Res Pract 236:153934","journal-title":"Pathol Res Pract"},{"issue":"2","key":"1968_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","volume":"119","author":"R Mehra","year":"2018","unstructured":"Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP et al (2018) Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer 119(2):153\u2013159","journal-title":"Br J Cancer"},{"key":"1968_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.annonc.2022.07.775","volume":"33","author":"MR da Dzienis","year":"2022","unstructured":"Dzienis MR, Fuentes JECCS, Hansen AR, Nordlinger MJ, Pastor AV, Oppelt P, Neki A, Gregg RW, Lima IPF, Franke FA, da Junior GF, Tseng JE, Loree T, Joshi AJ, Mccarthy JS, Naicker N, Sidi Y, Gumuscu B (2022) G. De Castro Jr. Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. Ann Oncol 33:295\u2013322","journal-title":"Ann Oncol"},{"issue":"9","key":"1968_CR36","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/biomedicines9091132","volume":"9","author":"\u0141J Adamski","year":"2021","unstructured":"Adamski \u0141J, Starzy\u0144ska A, Adamska P, Kunc M, Sakowicz-Burkiewicz M, Marvaso G et al (2021) High PD-L1 expression on tumor cells indicates worse overall survival in advanced oral squamous cell carcinomas of the tongue and the floor of the mouth but not in other oral compartments. Biomedicines 9(9):1132","journal-title":"Biomedicines"},{"issue":"9","key":"1968_CR37","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-13-2617","volume":"20","author":"PJ Schuler","year":"2014","unstructured":"Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y et al (2014) Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 20(9):2433\u20132444","journal-title":"Clin Cancer Res"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-026-01968-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-026-01968-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-026-01968-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:06:19Z","timestamp":1789725979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-026-01968-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1968"],"URL":"https:\/\/doi.org\/10.1007\/s12105-026-01968-2","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Study was conducted under an approved City of Hope Institutional Review Board (IRB) protocol, IRB #15198. All applicable ethical requirements were followed during the conduct of this study. Consent for publication has been obtained, and we confirm that we have completed all necessary preparations and disclosures required for this original manuscript submission.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that we have no known competing financial interests or personal relationships that could appear to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"97"}}